Cargando…
Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples
BACKGROUND: Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094901/ https://www.ncbi.nlm.nih.gov/pubmed/25024751 http://dx.doi.org/10.1186/1868-7083-6-13 |
_version_ | 1782325918008606720 |
---|---|
author | Stewart, David J Nunez, Maria I Jelinek, Jaroslav Hong, David Gupta, Sanjay Aldaz, Marcelo Issa, Jean-Pierre Kurzrock, Razelle Wistuba, Ignacio I |
author_facet | Stewart, David J Nunez, Maria I Jelinek, Jaroslav Hong, David Gupta, Sanjay Aldaz, Marcelo Issa, Jean-Pierre Kurzrock, Razelle Wistuba, Ignacio I |
author_sort | Stewart, David J |
collection | PubMed |
description | BACKGROUND: Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and phosphatase and tensin homolog (PTEN), immunohistochemistry scores from pre- and post-decitabine tumor biopsies (25 patients) were correlated with methylation of the long interspersed nuclear element-1 (LINE-1) repetitive DNA element (as a surrogate for global DNA methylation) and with tumor regression. RESULTS: With negative staining pre-decitabine (score = 0), the number of patients converting to positive staining post-decitabine was 1 of 1 for FHIT, 3 of 6 for WWOX, 2 of 3 for FUS1 and 1 of 10 for PTEN. In tumors with low pre-decitabine tumor suppressor gene scores (≤150), expression was higher post-treatment in 8 of 8 cases for FHIT (P = 0.014), 7 of 17 for WWOX (P = 0.0547), 7 of 12 for FUS1 (P = 0.0726), and 1 of 16 for PTEN (P = 0.2034). If FHIT, WWOX and FUS1 were considered together, median pre- versus post-decitabine scores were 60 versus 100 (P = 0.0002). Overall, tumor suppressor gene expression change did not correlate with LINE-1 demethylation, although tumors converting from negative to positive had a median decrease in LINE-1 methylation of 24%, compared to 6% in those not converting (P = 0.069). Five of 15 fully evaluable patients had reductions in tumor diameter (range 0.2% to 33.4%). Of these, three had simultaneous increases in three tumor suppressor genes (including the two patients with the greatest tumor regression) compared to 2 of 10 with tumor growth (P = 0.25). CONCLUSIONS: In tumors with low tumor suppressor gene expression, decitabine may be associated with increased expression of the tumor suppressor genes FHIT, FUS1, and WWOX, but not PTEN. |
format | Online Article Text |
id | pubmed-4094901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40949012014-07-15 Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples Stewart, David J Nunez, Maria I Jelinek, Jaroslav Hong, David Gupta, Sanjay Aldaz, Marcelo Issa, Jean-Pierre Kurzrock, Razelle Wistuba, Ignacio I Clin Epigenetics Research BACKGROUND: Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and phosphatase and tensin homolog (PTEN), immunohistochemistry scores from pre- and post-decitabine tumor biopsies (25 patients) were correlated with methylation of the long interspersed nuclear element-1 (LINE-1) repetitive DNA element (as a surrogate for global DNA methylation) and with tumor regression. RESULTS: With negative staining pre-decitabine (score = 0), the number of patients converting to positive staining post-decitabine was 1 of 1 for FHIT, 3 of 6 for WWOX, 2 of 3 for FUS1 and 1 of 10 for PTEN. In tumors with low pre-decitabine tumor suppressor gene scores (≤150), expression was higher post-treatment in 8 of 8 cases for FHIT (P = 0.014), 7 of 17 for WWOX (P = 0.0547), 7 of 12 for FUS1 (P = 0.0726), and 1 of 16 for PTEN (P = 0.2034). If FHIT, WWOX and FUS1 were considered together, median pre- versus post-decitabine scores were 60 versus 100 (P = 0.0002). Overall, tumor suppressor gene expression change did not correlate with LINE-1 demethylation, although tumors converting from negative to positive had a median decrease in LINE-1 methylation of 24%, compared to 6% in those not converting (P = 0.069). Five of 15 fully evaluable patients had reductions in tumor diameter (range 0.2% to 33.4%). Of these, three had simultaneous increases in three tumor suppressor genes (including the two patients with the greatest tumor regression) compared to 2 of 10 with tumor growth (P = 0.25). CONCLUSIONS: In tumors with low tumor suppressor gene expression, decitabine may be associated with increased expression of the tumor suppressor genes FHIT, FUS1, and WWOX, but not PTEN. BioMed Central 2014-07-03 /pmc/articles/PMC4094901/ /pubmed/25024751 http://dx.doi.org/10.1186/1868-7083-6-13 Text en Copyright © 2014 Stewart et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Stewart, David J Nunez, Maria I Jelinek, Jaroslav Hong, David Gupta, Sanjay Aldaz, Marcelo Issa, Jean-Pierre Kurzrock, Razelle Wistuba, Ignacio I Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples |
title | Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples |
title_full | Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples |
title_fullStr | Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples |
title_full_unstemmed | Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples |
title_short | Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples |
title_sort | impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes fhit, wwox, fus1 and pten in clinical tumor samples |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094901/ https://www.ncbi.nlm.nih.gov/pubmed/25024751 http://dx.doi.org/10.1186/1868-7083-6-13 |
work_keys_str_mv | AT stewartdavidj impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples AT nunezmariai impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples AT jelinekjaroslav impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples AT hongdavid impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples AT guptasanjay impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples AT aldazmarcelo impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples AT issajeanpierre impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples AT kurzrockrazelle impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples AT wistubaignacioi impactofdecitabineonimmunohistochemistryexpressionoftheputativetumorsuppressorgenesfhitwwoxfus1andpteninclinicaltumorsamples |